Sign in to fuzzto save your conversations, follow your research and come back anytime.
Dr. Lal Path Labs
SectorHealthcare
Dr Lal PathLabs is a leading diagnostic healthcare service provider in India. The company operates a nationwide network of medical laboratory centers, offering over 5000 diagnostic tests and related healthcare services. Its infrastructure includes a National Reference Laboratory in New Delhi, Regional Reference Labs in Kolkata, Bangalore, and Mumbai, 371 clinical laboratories, 5,102 patient service centers, and 10,938 pickup points as of March 31, 2023. The company provides services to individual patients, hospitals, healthcare providers, and corporate customers. Its test catalog includes 481 test panels, 2763 pathology tests, and 1947 radiology and cardiology tests. Dr Lal PathLabs has expanded through acquisitions and has several domestic and international subsidiaries. The company continues to grow its network and enhance its technological capabilities to improve its diagnostic services.
In the news
Dr Lal PathLabs faces ITAT appeal over ₹32.66 cr ESOP expense
Dr Lal PathLabs hits record high, targets ₹2,200+ levels
Dr Lal PathLabs acquires 80% stake in Ghana's Sunshine Healthcare
Diagnostics sector poised for strong FY27 growth amid stable pricing
MarketSmith India Recommends Dr. Lal Path Labs, Caplin Point
Dr Lal PathLabs Q1 profit jumps 27% to ₹170 crore, shares hit 52-week high
Nifty Falls 2.12% in Biggest Drop in 3 Months; Brokerage Picks
Dr Lal Path Labs hits ₹2,234.65 after Kotak double upgrade
The Quarter story
The two most recent quarterly results, compared side-by-side.
Dr Lal Pathlabs posts strong growth in Q1 FY27, with revenue and profits surging past previous peaks despite rising operational costs.
Revenue grew from ₹670 Cr in Q1 FY26 to ₹798 Cr in Q1 FY27, signaling robust top-line expansion.
Other expenses jumped from ₹124 Cr in Q1 FY26 to ₹150 Cr in Q1 FY27, indicating rising operational overheads.
EBITDA margin expanded from 28.7% in Q1 FY26 to 31.0% in Q1 FY27, showing improved operational efficiency.
Material costs climbed from ₹129 Cr in Q1 FY26 to ₹152 Cr in Q1 FY27, tracking higher test volumes.
Profit after tax rose from ₹134 Cr in Q1 FY26 to ₹170 Cr in Q1 FY27, underscoring strong net earnings.
Collection fees rose from ₹92 Cr in Q1 FY26 to ₹116 Cr in Q1 FY27, reflecting growing network costs.
Patient visits increased from 7.6 Mn in Q1 FY26 to 8.2 Mn in Q1 FY27, confirming steady demand growth.
Company insights, generated from the most recent coverage.
Trading window closed ahead of the Nov 4, 2026 Q2 FY27 board meeting removes insider buying support into the print, a mild near-term sentiment drag.
Down 3.18% to ₹1,888 on Sep 30, 2026 with no company-specific trigger — pure profit-booking after a 42.5% six-month rally.
One-month return of -2.2% versus +42.5% over six months — momentum has already rolled over, today's fall extends a mild drift rather than starting a new downtrend.